177lu-psma-617,cabazitaxel
emcure,sanofi,novartis
['crpc', 'cabazitaxel', 'therap ']
dr. updated the results of ph2 therap trial (lu177 psma vs cabazitaxel in mcrpc). somewhat disappointing to see no os benefit, even though 20% pts on cabazitaxel receiving lu177 post progression. #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer